4.7 Review

NanoBRET Approaches to Study Ligand Binding to GPCRs and RTKs

Journal

TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 39, Issue 2, Pages 136-147

Publisher

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2017.10.006

Keywords

-

Funding

  1. Australian Research Council (ARC) [LP130100037]
  2. UK Medical Research Council [MR/N020081/1]
  3. Biotechnology and Biological Sciences Research Council [BB/L019418/1, BB/L013827/1]
  4. Promega Corporation
  5. Innovative Medicines Initiative Joint Undertaking [115366]
  6. European Union's Seventh Framework Programme
  7. European Federation of Pharmaceutical Industries and Associations (EFPIA)
  8. BBSRC [BB/L013827/1, BB/L019418/1] Funding Source: UKRI
  9. MRC [MR/N020081/1] Funding Source: UKRI
  10. Medical Research Council [MR/N020081/1] Funding Source: researchfish

Ask authors/readers for more resources

Recent advances in the development of fluorescent ligands for G-protein-coupled receptors (GPCRs) and receptor tyrosine kinase receptors (RTKs) have facilitated the study of these receptors in living cells. A limitation of these ligands is potential uptake into cells and increased nonspecific binding. However, this can largely be overcome by using proximity approaches, such as bioluminescence resonance energy transfer (BRET), which localise the signal (within 10 nm) to the specific receptor target. The recent engineering of NanoLuc has resulted in a luciferase variant that is smaller and significantly brighter (up to tenfold) than existing variants. Here, we review the use of BRET from N-terminal NanoLuc-tagged GPCRs or a RTK to a receptor-bound fluorescent ligand to provide quantitative pharmacology of ligand-receptor interactions in living cells in real time.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available